Company profile: Oncodesign
1.1 - Company Overview
Company description
- Provider of precision medicine-driven oncology preclinical CRO services and biopharmaceutical R&D, developing anticancer therapies and leveraging platforms such as Nanocyclix for selective kinase inhibitors and OncoSNIPER AI for resistant patient stratification. Pipeline includes OPM-101 (RIPK2, IBD), OPM-102 (RIPK2, inflammation-related tumors), and an LRRK2 program (Parkinson’s), plus the IMODI cluster for cancer models and microbiota studies.
Products and services
- Nanocyclix®: Proprietary platform delivering access to highly potent and selective small‑molecule kinase inhibitors for novel and intractable kinases
- OncoSNIPER: AI-driven platform that identifies patient populations resistant to anti-cancer treatments and translates these signatures into therapeutic targets
- OPM-102: Preclinical-stage candidate targeting RIPK2 for the treatment of inflammation-related tumors, showing efficacy in colon carcinoma models
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oncodesign
Bioqual
HQ: United States
Website
- Description: Provider of AAALAC-accredited pre-clinical research and model development services, offering in vivo studies in small and large animal models, in vitro services (sample processing, virus stock generation, and assays including virus neutralization, hemagglutination inhibition, and quantitative PCR), vaccine evaluation (therapeutics and microbicides), drug therapy testing, and consulting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioqual company profile →
Liverpool ChiroChem
HQ: United Kingdom
Website
- Description: Provider of chiral small molecules for biotech/pharma R&D, offering specialist building blocks, fragments and screening compounds to enable small molecule drug discovery, plus ultra-large (1.4B), covalent (800k) and kinase-focused (4.5M) virtual libraries, DEL synthons, heterobifunctional linkers, and a parallel synthesis lab producing up to 5,000 compounds per month.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Liverpool ChiroChem company profile →
SSI Strategy
HQ: United States
Website
- Description: Provider of life sciences consulting combining business, medical, clinical, and pharmacovigilance expertise across the product lifecycle, including pre-clinical target identification, regulatory compliance, toxicology and FIH preparation; early development infrastructure and teams; late-stage evidence for regulatory approval, payer acceptance and patient outcomes; commercialization (launch and post-market support); and AI solutions via Metalmind.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SSI Strategy company profile →
Arcus Medica
HQ: United States
Website
- Description: Provider of medical and scientific communications consulting services with full-service capabilities and expertise in oncology, hematology, transplant, and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcus Medica company profile →
Apex Innovative Sciences
HQ: United States
Website
- Description: Provider of independent clinical trial site operations focused on central nervous system indications and other therapeutic areas, including neurology, psychiatry, and addiction, delivering high scientific and clinical quality for client partners and participants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apex Innovative Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oncodesign
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oncodesign
2.2 - Growth funds investing in similar companies to Oncodesign
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oncodesign
4.2 - Public trading comparable groups for Oncodesign
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →